These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35764817)

  • 1. External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy.
    Huang W; Zheng Y; Huang H; Cheng Y; Liu M; Chaphekar N; Wu X
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1447-1457. PubMed ID: 35764817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Evaluation of Population Pharmacokinetic Models for High-Dose Methotrexate in Adult Patients with Hematological Tumors.
    Chen S; Huang L; Huang W; Zheng Y; Shen L; Liu M; Chen W; Wu X
    J Clin Pharmacol; 2024 Apr; 64(4):437-448. PubMed ID: 38081138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.
    Han K; Bies R; Johnson H; Capitano B; Venkataramanan R
    Clin Pharmacokinet; 2011 Mar; 50(3):201-14. PubMed ID: 21294597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data.
    Kluwe F; Michelet R; Huisinga W; Zeitlinger M; Mikus G; Kloft C
    Clin Pharmacokinet; 2023 Oct; 62(10):1461-1477. PubMed ID: 37603216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients.
    Huang H; Liu Q; Zhang X; Xie H; Liu M; Chaphekar N; Wu X
    Front Pharmacol; 2022; 13():835037. PubMed ID: 35873594
    [No Abstract]   [Full Text] [Related]  

  • 6. Systematic external evaluation of reported population pharmacokinetic models of vancomycin in Chinese children and adolescents.
    Lv C; Lu J; Jing L; Liu TT; Chen M; Zhang R; Li C; Zhou S; Wei Y; Chen Y
    J Clin Pharm Ther; 2021 Jun; 46(3):820-831. PubMed ID: 33751618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.
    Zhao CY; Jiao Z; Mao JJ; Qiu XY
    Br J Clin Pharmacol; 2016 May; 81(5):891-907. PubMed ID: 26574188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients.
    Qin Y; Jiao Z; Ye YR; Shen Y; Chen Z; Chen YT; Li XY; Lv QZ
    J Glob Antimicrob Resist; 2023 Dec; 35():347-353. PubMed ID: 37573945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External evaluation of published population pharmacokinetic models of polymyxin B.
    Li YQ; Chen KF; Ding JJ; Tan HY; Yang N; Lin YQ; Wu CF; Xie YL; Yang GP; Liu JJ; Pei Q
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1909-1917. PubMed ID: 34342716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
    Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
    Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients.
    Wei S; Chen J; Zhao Z; Mei S
    Eur J Clin Pharmacol; 2023 Aug; 79(8):1031-1042. PubMed ID: 37261482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.
    Hoenigl M; Duettmann W; Raggam RB; Seeber K; Troppan K; Fruhwald S; Prueller F; Wagner J; Valentin T; Zollner-Schwetz I; Wölfler A; Krause R
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3262-7. PubMed ID: 23629724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.
    Farkas A; Daroczi G; Villasurda P; Dolton M; Nakagaki M; Roberts JA
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6806-6812. PubMed ID: 27600031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis.
    Zhang XZ; Huang XE; Xu YL; Zhang XQ; Su AL; Shen ZS
    Asian Pac J Cancer Prev; 2012; 13(5):2415-8. PubMed ID: 22901231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.
    McDougall DA; Martin J; Playford EG; Green B
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):165-77. PubMed ID: 26676909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients.
    Yang Y; Wang C; Chen Y; Wang X; Jiao Z; Wang Z
    Eur J Pharm Sci; 2023 Jul; 186():106416. PubMed ID: 37119861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models.
    Hwang MF; Beechinor RJ; Wade KC; Benjamin DK; Smith PB; Hornik CP; Capparelli EV; Duara S; Kennedy KA; Cohen-Wolkowiez M; Gonzalez D
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of voriconazole in adults.
    Hope WW
    Antimicrob Agents Chemother; 2012 Jan; 56(1):526-31. PubMed ID: 22064545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.